During CDMO Live Europe 2026, our CEO, Dr. Adriana Kiedzierska-Mencfeld joined a fireside chat to discuss the company’s evolution from a biologics developer to a dedicated CDMO, and how this experience continues to shape how we partner with clients.
Some of the key topics discussed include:
A foundation built on hands-on biologics experience
Rezon Bio’s CDMO capabities are built on years of developing, manufacturing and commercializing its own products. That experience gives our teams first-hand experience of the scientific, operational and regulatory challenges our clients face throughout the product lifecycle.
What clients expect from a CDMO partner
Having worked with CDMOs from the sponsor perspective, Dr.Adriana Kiedzierska-Mencfeld shared why transparency, responsiveness and shared accountability are essential to building trusted, long-term partnerships.
Looking beyond manufacturing
Successful CDMO partnerships require more than manufacturing capacity. Scientific expertise, open communication and proactive problem=solving help reduce risk, ccelerate development and support successful project delivery.
Building commercial readiness from day one
Successful programs require early consideration of manufacturability, scalability and price competitiveness to support efficient technology transfer, robust manufacturingand long-term commercial success.
The growing role of Central Europe in biologics manufacturing
Central Europe is becoming an increasingly attractive location for biologics
development and manufacturing, combining strong scientific talent, high regulatory standards and competitive operating models. Rezon Bio brings together Contral Europe’s advantages with proven biologics expertise to help clients accelerate development and manufacturing.
Listen to the full podcast below:
Expert Insights
